Epithelial Ovarian Cancer: A Detailed Look at Causes, Symptoms, Diagnosis, and Treatments

If you or a loved one has been diagnosed with epithelial ovarian cancer, you may be searching for comprehensive information to help you understand this disease and navigate your journey.

Epithelial ovarian cancer is the most common type of ovarian cancer, accounting for about 90% of all ovarian cancer cases. This cancer develops in the epithelial cells, which form the outer layer of the ovaries.

Epithelial ovarian cancer can also originate in the fallopian tubes or the peritoneum (the lining of the abdominal cavity). These cancers are often grouped together with ovarian cancer because they share similar features and treatments.

According to the American Cancer Society, a woman’s lifetime risk of developing ovarian cancer is about 1 in 91, and her lifetime risk of dying from it is about 1 in 143. 

The ACS estimates roughly 21,010 new ovarian cancer diagnoses and 12,450 deaths in the United States. Those figures don’t include borderline (low malignant potential) tumors, which are counted separately.

Epithelial Ovarian Cancer Types

There are several types of epithelial ovarian cancer, each with its own characteristics and prognosis:

High-Grade Serous Ovarian Carcinoma (HGSOC)

As the most prevalent subtype, HGSOC accounts for approximately three-quarters of all epithelial ovarian cancers. 

Histologic, molecular, and genetic evidence now suggests that as many as 80% of tumors classified as high-grade serous carcinoma of the ovary or peritoneum may actually have started in the fimbrial end of the fallopian tube. That finding reshaped how researchers think about where this disease begins. It’s the reason fallopian tube lesions like STIC and p53 signatures are now taken so seriously, and the reason a salpingectomy has entered the prevention conversation.

Once HGSOC reaches the ovaries, it spreads quickly to the peritoneum and other organs, where deposits known as peritoneal implants often form. 

Around 70% of HGSOC cases are diagnosed at an advanced stage (stage 3 or 4), by which time the cancer has already metastasized. If you want a side-by-side comparison of the two serous subtypes, our guide to LGSOC vs HGSOC breaks down how differently they behave.

Endometrioid Carcinoma

This subtype frequently occurs in individuals with endometriosis and primarily affects the uterus’s inner lining (endometrium). 

Compared to other epithelial ovarian cancer subtypes, endometrioid carcinomas generally exhibit a better response to chemotherapy. The connection between endometriosis and ovarian cancer is real, though the absolute risk for any individual with endometriosis remains low.

Low-Grade Serous Ovarian Carcinoma (LGSOC)

Comprising about 10% of epithelial ovarian cancers, low-grade serous ovarian cancer is a slow-growing subtype that tends to affect younger individuals, typically between the ages of 40 and 60. Despite its generally better prognosis compared to high-grade serous carcinoma, LGSOC frequently subjects patients to prolonged periods of ineffective therapies and poor quality of life.

For years, LGSOC had no FDA-approved treatment at all. That changed in 2025, when the FDA granted accelerated approval to the combination of avutometinib and defactinib for adults with KRAS-mutated recurrent LGSOC who have had at least one prior systemic treatment. 

It’s a genuine milestone. But the approval doesn’t cover high-grade serous disease, and it doesn’t cover LGSOC without the required KRAS mutation. Which means a large share of low-grade patients still have no approved option designed for their disease.

For a full rundown of what’s available today and what’s still in development, see our guide to LGSOC drugs.

Mucinous Carcinoma

These distinct tumors often grow to a substantial size, measuring up to 8 inches (20 centimeters) in diameter. Mucinous ovarian cancer generally responds well to treatment and is typically confined to the ovaries.

Ovarian Clear Cell Carcinoma (OCCC)

Individuals of Asian descent and those with endometriosis have a higher risk of developing clear cell ovarian cancer. This subtype is frequently diagnosed at an advanced stage and exhibits resistance to chemotherapy.

Borderline Ovarian Tumors (BOT)

Borderline ovarian tumors (or low malignant potential tumors, or BOTs) account for approximately 15% of all epithelial ovarian tumors. BOTs are characterized by atypical cell growth without invasion into the stromal tissue. 

Borderline tumors (also called borderline ovarian cancer) commonly affect younger women and have a very good prognosis. Treatment mainly involves surgical removal of the tumor, with chemotherapy rarely being necessary. However, close monitoring is crucial, as recurrences can occur.

Want to go deeper? Read more about the types of borderline ovarian tumors and what the research says about borderline ovarian tumor prognosis.

Rarer Epithelial Subtypes

A small number of epithelial tumors fall outside these categories. Primary squamous cell carcinoma of the ovary, for instance, is exceptionally rare and usually arises from benign conditions such as ovarian cysts, endometriosis, or Brenner tumors. 

Because these subtypes are so uncommon, evidence to guide treatment is thin, and a referral to a specialist center matters even more. Our overview of rare ovarian cancer subtypes covers what’s known.

It’s essential to recognize that each subtype of epithelial ovarian cancer possesses unique characteristics, and treatment strategies are personalized based on factors such as the cancer stage, grade, and the patient’s overall health.

Risk Factors for Epithelial Ovarian Cancer

Several factors can increase a woman’s risk of developing epithelial ovarian cancer, including:

• Age: The risk increases as women get older, with most cases occurring after menopause.
• Family history: Women with a first-degree relative (mother, daughter, or sister) who has had ovarian cancer have an increased risk.
• Genetic mutations: Inherited ovarian cancer mutations in tumor suppressor genes like BRCA1 and BRCA2 can significantly increase your risk.
• Other factors: Obesity, endometriosis, and never having been pregnant may also increase the risk.

For a fuller picture, see our guide to ovarian cancer risk factors.

Epithelial Ovarian Cancer Symptoms

Early-stage epithelial ovarian cancer rarely causes noticeable symptoms, which is why most cases are diagnosed at advanced stages. 

However, it’s essential to be aware of your body and pay attention to any persistent changes or symptoms that concern you. As the cancer progresses, women may experience:

• Bloating or swelling in the abdomen
• Pelvic pain or pressure
• Difficulty eating or feeling full quickly
• Urinary symptoms (urgency or frequency)
• Fatigue
• Back pain

If these symptoms persist for more than a few weeks, it’s important to trust your instincts and see a healthcare provider for evaluation. While these symptoms can be caused by other conditions, it’s crucial not to dismiss them. Remember, you know your body best, and advocating for your health is essential.

It’s also important to note that some women may experience more subtle symptoms or changes in their bodies. These could include:

• Unexplained weight loss or weight gain
• Changes in bowel habits (constipation or diarrhea)
• Menstrual irregularities (for women who still have periods)
• Pain during intercourse

If you notice any of these symptoms, don’t hesitate to discuss them with your healthcare provider. They can help determine the cause and recommend appropriate tests or treatments. 

(Our full breakdown of ovarian cancer symptoms covers what to track and how to describe it to your doctor.)

Remember, early detection is key to improving outcomes for women with epithelial ovarian cancer. While it can be scary to think about the possibility of cancer, it’s important to prioritize your health and well-being. 

Trust your instincts, tune in to your body’s signals, and don’t be afraid to seek help when you need it. Your healthcare team is here to support you every step of the way.

Diagnosis of Epithelial Ovarian Cancer

It’s important to note that there is currently no reliable way to screen for ovarian cancer in women who do not have any signs or symptoms. 

While some tests, such as pelvic exams, ultrasounds, and CA-125 blood tests, may be used to detect ovarian cancer, they have not been proven effective for widespread screening. This is why women must be aware of their bodies and report any persistent symptoms to their healthcare provider.

If you experience symptoms that could be related to ovarian cancer, your healthcare provider will likely start the diagnostic process with the following steps:

• Pelvic exam: During this exam, your healthcare provider will manually check for any abnormalities in your ovaries, uterus, and other pelvic organs.
• CA-125 blood test: This test measures the level of a protein called CA-125 in your blood. Elevated levels may indicate the presence of ovarian cancer, but it’s important to note that other conditions, such as endometriosis or pelvic inflammatory disease, can also cause increased CA-125 levels. The test involves a simple blood draw and can usually be done in your healthcare provider’s office or at a lab.  

If the results of these initial tests suggest the possibility of ovarian cancer, your healthcare provider may recommend the following imaging tests:

• Ultrasound: This test uses sound waves to create images of your ovaries and other pelvic organs. You’ll lie on an exam table, and a technician will apply a gel to your abdomen and move a transducer (a small device that emits sound waves) over your skin. In some cases, a transvaginal ultrasound may be performed, in which a small transducer is inserted into your vagina to get a closer look at your ovaries.
• CT scan or MRI: These imaging tests provide more detailed pictures of your ovaries and surrounding organs. Both tests usually take 30 to 60 minutes and may require you to hold your breath for short periods.

Additional Testing

When ovarian cancer is suspected, doctors usually avoid performing incisional or needle biopsies due to the potential risk of causing cancer cells to spread. However, in certain situations, these types of biopsies may be conducted on other parts of the body to determine if the ovarian cancer has spread (metastasized).

If initial tests and examinations indicate the likelihood of ovarian cancer, a surgical biopsy involving the removal of tissue (excisional biopsy) is necessary for confirmation. At this point in the diagnostic process, it is recommended that patients consult with a gynecologic oncologist before undergoing surgery.

If cancer is confirmed, additional tests, such as PET scans or chest X-rays, may be done to determine the stage of the cancer and whether it has spread to other parts of the body. This information helps your healthcare team develop an appropriate treatment plan. 

Our guide to ovarian cancer staging explains what each FIGO stage means. At many cancer centers, your case will also go before a tumor board, where specialists from different disciplines review it together before a plan is finalized.

Genetic Testing and Tumor Testing: You Need Both

This is the step patients most often have to ask for. Don’t skip it.

The American Society of Clinical Oncology recommends that every woman diagnosed with epithelial ovarian cancer be offered germline genetic testing for BRCA1, BRCA2, and other ovarian cancer susceptibility genes, regardless of her clinical features or family cancer history. 

For women who don’t carry a germline BRCA1/2 variant, somatic tumor testing for BRCA1/2 should be performed. ASCO also recommends somatic testing for mismatch repair deficiency (dMMR) in women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer. A dMMR result can also point toward Lynch syndrome, an inherited condition that raises the risk of several cancers, including ovarian.

The NCCN guidelines for ovarian cancer go a step further on the tumor side, recommending that upfront somatic testing identify the molecular alterations that can actually change treatment, including BRCA1 and BRCA2, loss of heterozygosity, or homologous recombination deficiency (HRD) status when there’s no germline BRCA mutation. Those guidelines matter for a second reason, too: insurers lean on them when deciding what to cover.

Why does this matter so much? Because these results open doors:

• A germline BRCA mutation can qualify you for a PARP inhibitor and tells your blood relatives something urgent about their own risk.
• HRD status helps predict how well PARP inhibitors are likely to work.
• A KRAS mutation in low-grade serous disease is what determines eligibility for the only FDA-approved LGSOC combination.
• dMMR or PD-L1 results can open the door to immunotherapy.

Germline mutations are inherited and found through a blood or saliva sample. Somatic mutations happen inside the tumor itself and are found by testing tumor tissue. You can have one without the other, and testing only your blood can miss a mutation that would have changed your treatment plan. If you want to understand the most common test by name, start with BRCA testing for ovarian cancer.

Ask your oncologist directly: Have I had both germline and somatic testing? What was my HRD status? Can I see the report?

Throughout the diagnostic process, it’s essential to communicate openly with your healthcare team and ask questions about any concerns you may have. Remember, your providers are there to support you and help you navigate this challenging time with the most accurate information and compassionate care possible.

Treatment Options for Epithelial Ovarian Cancer

Treatment for epithelial ovarian cancer depends on the stage and type of the cancer, as well as the woman’s overall health. The primary goal of treatment is to remove as much of the cancer as possible and prevent its spread. For a broader overview, see our guide to ovarian cancer treatment.

Common treatments include:

Surgery

The first step in treating epithelial ovarian cancer is typically surgery to remove as much of the tumor as possible, a procedure known as debulking surgery. 

Depending on the extent of the cancer, this may involve removing one or both ovaries, the fallopian tubes, the uterus, and nearby lymph nodes. In some cases, parts of other organs, such as the omentum (a fatty apron that covers the abdominal organs), may also need to be removed.

Debulking surgery for ovarian cancer aims to leave behind no visible cancer or only small tumors less than 1 cm in size. This is known as optimal debulking and has been shown to improve outcomes and survival rates for women with advanced epithelial ovarian cancer. 

If optimal debulking is not possible, the surgeon will remove as much of the tumor as safely possible, which is called suboptimal debulking.

If you or a loved one has been diagnosed with ovarian epithelial cancer and surgery is being considered as part of the initial treatment plan, it’s crucial to seek care from a gynecologic oncologist. These specialists have extensive training and expertise in managing gynecological cancers, including ovarian cancer. 

Research has shown that patients who undergo surgery performed by a gynecologic oncologist tend to have better outcomes compared to those treated by other types of surgeons.

When discussing your treatment options, make sure to ask your healthcare provider about the possibility of being referred to a gynecologic oncologist for your surgical management. Advocating for yourself or your loved one to receive the most appropriate and specialized care can make a significant difference in the overall outcome and quality of life.

It’s important to follow your healthcare team’s instructions for post-operative care and attend follow-up appointments to monitor your recovery.

When Chemotherapy Comes First

Surgery isn’t always step one. 

For many women with advanced disease, tumors are too widespread to remove safely at the outset. In that situation, the care team may recommend neoadjuvant chemotherapy: a few cycles of chemo to shrink the disease first, followed by interval debulking surgery, followed by the rest of the chemotherapy.

In 2025, ASCO published an updated guideline on this, endorsed by the Society of Gynecologic Oncology. The recommendation hinges on one thing: whether your surgeon can realistically remove all visible disease. 

For patients with newly diagnosed advanced epithelial ovarian cancer who are fit for surgery and have a high likelihood of achieving complete cytoreduction, primary cytoreductive surgery is recommended. For patients who are fit for surgery but unlikely to achieve complete cytoreduction, neoadjuvant chemotherapy is recommended instead.

That same guideline makes two other points worth knowing. Anyone with suspected stage 3 or 4 disease should be evaluated by a gynecologic oncologist, with CA-125, a CT of the abdomen and pelvis, and chest imaging. And every patient with epithelial ovarian cancer should be offered germline and somatic testing at diagnosis. After interval surgery, chemotherapy continues to complete a six-cycle plan, with bevacizumab as an option.

Being offered chemo first is not a sign that your case is hopeless. It’s often a strategic decision aimed at getting you to a complete surgical result that wouldn’t have been possible on day one. Ask your surgeon which path they’re recommending and why.

HIPEC

Some patients having interval debulking surgery may also be offered HIPEC, or hyperthermic intraperitoneal chemotherapy. Heated chemotherapy is delivered directly into the abdominal cavity during surgery, washing the area where microscopic disease tends to hide.

HIPEC is reserved for carefully selected patients. The 2025 ASCO guideline reviewed the newer evidence on adding HIPEC at the time of interval cytoreductive surgery and stopped short of endorsing it for everyone, partly because it’s resource-intensive and not available at every center. 

It typically comes up for patients with stage 3 disease who weren’t candidates for primary surgery, who responded to neoadjuvant platinum chemotherapy, who are in good overall health, and whose surgery achieved an optimal result. If you’re facing interval debulking, it’s a fair question to raise with your surgeon.

Chemotherapy

After surgery, most women with epithelial ovarian cancer will receive chemotherapy for ovarian cancer to destroy any remaining cancer cells. 

Chemotherapy drugs are typically administered intravenously (through a vein) or intraperitoneally (directly into the abdominal cavity). The most common chemotherapy regimen for epithelial ovarian cancer is a combination of carboplatin and paclitaxel, given in cycles every 3 to 4 weeks for a total of 6 cycles.  

Chemotherapy can cause side effects such as nausea, fatigue, hair loss, and an increased risk of infection when your white blood cell count drops, a condition called neutropenia.

Your healthcare team can help you manage these side effects with medications and supportive care. It’s important to communicate any concerns you have about side effects with your team so they can help you find the best solutions. Our guide to ovarian cancer chemotherapy side effects walks through what to expect and what actually helps.

Targeted Therapy

Targeted therapies are drugs that go after specific molecules involved in cancer cell growth and survival, rather than attacking all fast-dividing cells the way chemotherapy does. 

For example, bevacizumab (Avastin) blocks the growth of new blood vessels that feed tumors.

Another transformative addition has been the PARP inhibitor. These medications work by obstructing PARP, a protein vital for repairing damaged DNA within cancer cells, thus impeding their ability to survive and proliferate. 

They have shown effectiveness, particularly in patients with BRCA mutations, as these mutations make cancer cells more reliant on PARP for DNA repair. 

PARP inhibitors have expanded treatment options and improved outcomes for many patients with ovarian cancer, offering a targeted approach with potentially fewer side effects compared to traditional chemotherapy.

For low-grade serous disease, targeted therapy looks different. The KRAS and MEK pathways drive much of LGSOC’s behavior, which is why BRAF and MEK inhibitors have become such a focus of research, and why the avutometinib and defactinib combination received accelerated FDA approval for KRAS-mutated recurrent LGSOC after at least one prior systemic treatment. Again, the approval requires a KRAS mutation, and it does not extend to high-grade serous ovarian cancer.

Maintenance Therapy: What Happens After Chemo Ends

Finishing chemotherapy doesn’t always mean finishing treatment.

Many women move on to maintenance therapy, which is designed to keep the cancer from coming back or to delay its return. Maintenance may involve a PARP inhibitor, bevacizumab, or both, and it can continue for months or years. Your eligibility depends heavily on your testing results, particularly BRCA status and HRD status, which is one more reason the genetic and tumor testing conversation matters so much at diagnosis.

You’ll also keep having scans during this phase. Radiologists and oncologists typically interpret them using RECIST criteria, a standardized way of measuring whether disease is shrinking, holding steady, or growing. Knowing the language helps you read your own reports.

Maintenance therapy comes with its own side effect profile and its own emotional weight. Many patients describe it as a strange limbo between treatment and survivorship. If you’re in it, you’re not imagining the difficulty. 

Our guide to ovarian cancer and mental health covers that feeling honestly, and our breakdown of ovarian cancer treatment side effects offers coping strategies for the long haul.

New Options for Platinum-Resistant Disease

When ovarian cancer recurrence happens within six months of completing platinum-based chemotherapy, the disease is called platinum-resistant. It has long been one of the hardest situations in gynecologic oncology. Two approvals in 2026 changed the landscape:

Pembrolizumab (Keytruda) with paclitaxel. In 2026, the FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received one or two prior systemic therapies and whose tumors express PD-L1, as determined by the PD-L1 IHC 22C3 pharmDx test. 

That companion diagnostic was approved at the same time. This is the first immunotherapy approval specific to these tumor types.

Relacorilant (Lifyorli) with nab-paclitaxel. The FDA also approved relacorilant, a first-in-class glucocorticoid receptor antagonist, in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. 

The approval was based on the phase 3 ROSELLA trial, which enrolled 381 patients. Median progression-free survival was 6.5 months with relacorilant plus nab-paclitaxel, compared with 5.5 months with nab-paclitaxel alone.

Both approvals depend on eligibility criteria and biomarker results, so ask your oncologist whether either applies to your situation.

Immunotherapy

Immunotherapy works by harnessing the body’s own immune system to target and destroy cancer cells. Until recently, its role in ovarian cancer was largely experimental. Earlier use of pembrolizumab in these tumors was limited to tumor-agnostic biomarkers like microsatellite instability and high tumor mutational burden, which apply to only a small slice of patients.

The pembrolizumab approval changed that, making immunotherapy a standard therapeutic option for eligible patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer. Learn more in our guide to immunotherapy for ovarian cancer.

Other immunotherapy approaches remain under investigation, including:

• CAR-T cell therapy: Chimeric Antigen Receptor T-cell therapy involves genetically modifying a patient’s own immune cells to better recognize and attack cancer cells. It has shown promising results in certain blood cancers and is now being explored for solid tumors like ovarian cancer.
• Cancer vaccines: Designed to stimulate the immune system to recognize and attack cancer cells.
• Adoptive cell transfer: Collecting immune cells from a patient, modifying them in the laboratory, and reinfusing them.

Radiation Therapy

Radiation therapy is rarely used in the United States as a primary treatment for ovarian cancer. When it is used, it’s usually targeted at a specific site, often to relieve symptoms such as ovarian cancer pain or bleeding, or to treat an isolated area of recurrent disease.

Unlike chemotherapy, which circulates throughout the body, radiation is localized and aims to minimize damage to surrounding healthy tissue. If radiation is raised as part of your plan, ask your oncologist what specific goal it’s meant to accomplish.

Clinical Trials

Clinical trials can be a great opportunity to access new treatments. Trials provide patients with the opportunity to receive therapies that could potentially be more effective, but which are not yet widely available. Some patients may experience better outcomes or longer survival by participating, especially when standard treatments have been exhausted or aren’t working.

This matters enormously for rare subtypes. Trials are often where the only meaningful options exist for LGSOC and borderline patients. 

Your healthcare team will work with you to develop a personalized treatment plan based on your specific diagnosis, medical history, and personal preferences. Don’t hesitate to ask questions and express any concerns you may have about your treatment options. 

If you’re not sure where to start, here are the ovarian cancer questions worth bringing to your next appointment. It’s important to feel informed and empowered in making decisions about your care. And if something doesn’t sit right, an ovarian cancer second opinion is always your right.

This article is for informational purposes and is not a substitute for medical advice. Treatment decisions should always be made with your gynecologic oncologist, who knows your full clinical picture.

Prognosis and Survival Rates

Important note: Ovarian cancer survival rates have been improving steadily over the years due to advancements in detection and treatment. While these rates are based on large population studies and serve as a general guide, they don’t necessarily reflect individual situations and they do not definitively predict any one person’s journey with ovarian cancer.

A gynecologic oncologist should be able to answer your questions and offer a more accurate prognosis. They can take your personal circumstances into account and build a tailored treatment plan. Factors such as the specific type of ovarian cancer, stage at diagnosis, overall health, and response to treatment all play a role.

How the numbers are grouped. The survival statistics you’ll find online usually come from the SEER database, which doesn’t use FIGO stage numbers. 

Instead it sorts cases into three buckets: localized (no sign the cancer has spread outside the ovaries), regional (spread to nearby structures or lymph nodes), and distant (spread to distant parts of the body). So a SEER “regional” figure is not the same thing as a stage 3 figure, which is a common source of confusion.

For invasive epithelial ovarian cancer, based on people diagnosed between 2015 and 2021, the American Cancer Society reports 5-year relative survival rates of 92% for localized disease, 71% for regional disease, and 32% for distant disease. Across all SEER stages combined, the figure is 51%.

The share of ovarian cancers diagnosed at a distant stage fell to 49% in 2018 through 2022, down from 57% a decade earlier.

Other factors that shape prognosis:

• Type: Some subtypes, such as endometrioid carcinoma and mucinous carcinoma, tend to have better outcomes than high-grade serous ovarian carcinoma, which is more aggressive and often diagnosed at advanced stages.
• Other factors: Younger age at diagnosis, good overall health, and optimal surgical removal of the tumors can also improve prognosis.

It’s important to remember that survival rates are based on population averages and may not reflect an individual’s unique situation. Some women with advanced ovarian cancer can have long-term remissions, while others with early-stage disease may experience recurrences. 

And because these statistics are drawn from people diagnosed at least five years ago, they can’t capture the newest treatments. Discussing your specific prognosis with your healthcare team can help you better understand your situation and make informed decisions.

Living with Epithelial Ovarian Cancer

A diagnosis of epithelial ovarian cancer can be overwhelming, but remember that everyone’s journey is unique. 

It’s essential to tune in to what your body is telling you and trust your instincts throughout this process. Don’t hesitate to ask for help when you need it. Your healthcare team, ovarian cancer support groups, counselors, and loved ones are all here to help you navigate this challenging time.

As you undergo treatment and cope with the physical and emotional challenges of ovarian cancer, it’s important to treat your body with kindness. Practice self-care by nourishing your body with an ovarian cancer diet built on real evidence, staying active when possible, and getting enough rest. Be gentle with yourself and acknowledge that some days may be harder than others.

Empowering yourself through body literacy, which means deepening your understanding of your body’s needs and signals, can be a valuable tool in managing your health. Pay attention to any changes or symptoms you experience, and communicate openly with your healthcare team about your concerns. 

Our guide to self-advocacy after an ovarian cancer diagnosis offers 14 practical ways to make your voice heard in the exam room.

Remember, you are not alone in this journey. There is a community of survivors, advocates, and healthcare professionals ready to offer support, resources, and guidance.

Start with Your Subtype

Epithelial ovarian cancer isn’t one disease. It’s a collection of them, and the specific subtype on your pathology report shapes nearly everything that follows: your treatment options, your monitoring schedule, the questions worth asking.

So start there. Know your subtype. Make sure you’ve had both germline and tumor testing. Get your care from a gynecologic oncologist. And keep asking questions until the answers make sense to you, because the people who do tend to get better care.

None of this is simple. But it is knowable, and you don’t have to figure it out alone.